Analyst Brendan Smith of TD Cowen maintained a Buy rating on Ginkgo Bioworks Holdings, reducing the price target to $14.00.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Brendan Smith has given his Buy rating due to a combination of factors that highlight Ginkgo Bioworks Holdings’ potential for future growth. Despite a significant year-over-year decline in revenues, the company’s performance in the third quarter met expectations, and management has reaffirmed its guidance for fiscal year 2025. This indicates confidence in Ginkgo’s ability to achieve its revenue targets, particularly in the biosecurity and cell engineering segments.
Furthermore, the company’s strategic focus on automation and artificial intelligence is expected to drive medium-term growth, offering potential upside to current estimates. While macroeconomic uncertainties and a slowdown in the pharmaceutical sector pose challenges, Ginkgo’s diversified revenue streams and growth strategy provide a solid foundation for future expansion. As such, Brendan Smith believes that the company’s long-term value proposition remains intact, justifying the Buy rating with a revised price target of $14.